Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Taliglucerase Alfa

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer`s Biologic Elelyso Receives Suppl Approval in US
    Pfizer`s Biologic Elelyso Receives Suppl Approval in US

    17 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458

    FDA
    17 Jan 2025
    Share Share
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Suppl Approvals in US
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Suppl Approvals in US

    10 Jul 2024

    // Taliglucerase Alfa -- PB000469 FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458

    Taliglucerase Alfa -- PB000469 FDA
    10 Jul 2024
    Share Share
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Approval in the U.S.
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Approval in the U.S.

    09 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458

    FDA
    09 May 2023
    Share Share
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Approval in the U.S.
    Pfizer's Biologic Elelyso (Taliglucerase Alfa) Receives Approval in the U.S.

    30 Aug 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458

    FDA
    30 Aug 2022
    Share Share
    Pfizer`s Elelyso (Taliglucerase Alfa) Receives Supplemental Approval In U.S
    Pfizer`s Elelyso (Taliglucerase Alfa) Receives Supplemental Approval In U.S

    06 Nov 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458

    FDA
    06 Nov 2020
    Share Share
    Enforcement Report - Week of March 11, 2020
    Enforcement Report - Week of March 11, 2020

    12 Mar 2020

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-11-2020-1583989701.pdf

    FDA
    12 Mar 2020
    Share Share